| Basics |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
|
| IPO Date: |
May 28, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$62.13B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.70 | 2.19%
|
| Avg Daily Range (30 D): |
$5.84 | 1.26%
|
| Avg Daily Range (90 D): |
$5.75 | 1.42%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.55M |
| Avg Daily Volume (30 D): |
.81M |
| Avg Daily Volume (90 D): |
.88M |
| Trade Size |
| Avg Trade Size (Sh.): |
78 |
| Avg Trade Size (Sh.) (30 D): |
35 |
| Avg Trade Size (Sh.) (90 D): |
38 |
| Institutional Trades |
| Total Inst.Trades: |
10,540 |
| Avg Inst. Trade: |
$6.99M |
| Avg Inst. Trade (30 D): |
$35.26M |
| Avg Inst. Trade (90 D): |
$27.3M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$12.36M |
| Avg Closing Trade (30 D): |
$63.6M |
| Avg Closing Trade (90 D): |
$58.06M |
| Avg Closing Volume: |
81.67K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-2.47
|
$-.51
|
$-.44
|
|
Diluted EPS
|
$-2.47
|
$-.51
|
$-.44
|
|
Revenue
|
$ 2.46B
|
$ 773.69M
|
$ 594.19M
|
|
Gross Profit
|
$ 2.07B
|
$ 631.66M
|
$ 524.01M
|
|
Net Income / Loss
|
$ -319.09M
|
$ -66.28M
|
$ -57.48M
|
|
Operating Income / Loss
|
$ -180.19M
|
$ -16.2M
|
$ 18.08M
|
|
Cost of Revenue
|
$ 396.84M
|
$ 142.03M
|
$ 70.18M
|
|
Net Cash Flow
|
$ 144.67M
|
$ 93.61M
|
$ 53.6M
|
|
PE Ratio
|
|
|
|
|
|
|
